These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Development of a Shigella conjugate vaccine targeting Shigella flexneri 6 that is immunogenic and provides protection against virulent challenge. Kelly M; Janardhanan J; Wagh C; Verma S; Charles RC; Leung DT; Kamruzzaman M; Pansuriya RK; Chowdhury F; Vann WF; Kaminski RW; Khan AI; Bhuiyan TR; Qadri F; Kováč P; Xu P; Ryan ET Vaccine; 2024 Oct; 42(24):126263. PubMed ID: 39217775 [TBL] [Abstract][Full Text] [Related]
11. Construction of a multivalent vaccine strain of Shigella flexneri and evaluation of serotype-specific immunity. Jennison AV; Roberts F; Verma NK FEMS Immunol Med Microbiol; 2006 Apr; 46(3):444-51. PubMed ID: 16553820 [TBL] [Abstract][Full Text] [Related]
12. A Novel Ndungo E; Randall A; Hazen TH; Kania DA; Trappl-Kimmons K; Liang X; Barry EM; Kotloff KL; Chakraborty S; Mani S; Rasko DA; Pasetti MF mSphere; 2018 Aug; 3(4):. PubMed ID: 30068560 [No Abstract] [Full Text] [Related]
13. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children. Passwell JH; Ashkenazi S; Harlev E; Miron D; Ramon R; Farzam N; Lerner-Geva L; Levi Y; Chu C; Shiloach J; Robbins JB; Schneerson R; Pediatr Infect Dis J; 2003 Aug; 22(8):701-6. PubMed ID: 12913770 [TBL] [Abstract][Full Text] [Related]
14. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine. Oaks EV; Turbyfill KR Vaccine; 2006 Mar; 24(13):2290-301. PubMed ID: 16364513 [TBL] [Abstract][Full Text] [Related]
15. Mapping the functional B-cell epitopes of Li S; Zhang W Appl Environ Microbiol; 2024 Aug; 90(8):e0098824. PubMed ID: 39082807 [No Abstract] [Full Text] [Related]
16. Protective efficacy of oral immunization with heat-killed Shigella flexneri 2a in animal model: study of cross protection, immune response and antigenic recognition. Mukhopadhaya A; Mahalanabis D; Khanam J; Chakrabarti MK Vaccine; 2003 Jun; 21(21-22):3043-50. PubMed ID: 12798648 [TBL] [Abstract][Full Text] [Related]
17. Shigella outer membrane protein PSSP-1 is broadly protective against Shigella infection. Kim JO; Rho S; Kim SH; Kim H; Song HJ; Kim EJ; Kim RY; Kim EH; Sinha A; Dey A; Yang JS; Song MK; Nandy RK; Czerkinsky C; Kim DW Clin Vaccine Immunol; 2015 Apr; 22(4):381-8. PubMed ID: 25651919 [TBL] [Abstract][Full Text] [Related]
18. Development of recombinant vaccine candidate molecule against Shigella infection. Chitradevi STS; Kaur G; Sivaramakrishna U; Singh D; Bansal A Vaccine; 2016 Oct; 34(44):5376-5383. PubMed ID: 27591952 [TBL] [Abstract][Full Text] [Related]
19. Immunization of Mice with a Live Transconjugant Shigella Hybrid Strain Induced Th1 and Th17 Cell-Mediated Immune Responses and Confirmed Passive Protection Against Heterologous Shigellae. Nag D; Koley H; Sinha R; Mukherjee P; Sarkar C; Withey JH; Gachhui R Scand J Immunol; 2016 Feb; 83(2):92-101. PubMed ID: 26478541 [TBL] [Abstract][Full Text] [Related]
20. Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection. Talaat KR; Alaimo C; Martin P; Bourgeois AL; Dreyer AM; Kaminski RW; Porter CK; Chakraborty S; Clarkson KA; Brubaker J; Elwood D; Frölich R; DeNearing B; Weerts H; Feijoo BL; Halpern J; Sack D; Riddle MS; Fonck VG EBioMedicine; 2021 Apr; 66():103310. PubMed ID: 33862589 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]